Rein Therapeutics (RNTX) Cash from Investing Activities (2016 - 2023)

Rein Therapeutics (RNTX) has reported Cash from Investing Activities for 8 consecutive years, with -$96000.0 the latest figure, recorded in Q4 2023.

• In Q4 2023, Cash from Investing Activities fell 102.02% year-over-year to -$96000.0; the TTM figure through Sep 2024 stood at -$96000.0 (down 100.46% YoY), while the FY2023 annual figure was $16.2 million, down 38.79% from the prior year.
• Cash from Investing Activities fell to -$96000.0 in Q4 2023 per RNTX's latest filing, from $542000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $11.6 million in Q1 2022 and bottomed at -$37.5 million in Q1 2021.
• Historically, Cash from Investing Activities has averaged $516750.0 across 5 years, with a median of $3.9 million in 2019.
• On a YoY basis, Cash from Investing Activities climbed as much as 730.53% in 2021 and fell as far as 2107.53% in 2021.
• Rein Therapeutics' Cash from Investing Activities stood at $4.8 million in 2019, then sank by 107.49% to -$357000.0 in 2020, then jumped by 730.53% to $2.3 million in 2021, then soared by 111.64% to $4.8 million in 2022, then tumbled by 102.02% to -$96000.0 in 2023.
• Business Quant data shows RNTX's Cash from Investing Activities at -$96000.0 in Q4 2023, $542000.0 in Q3 2023, and $8.5 million in Q2 2023.